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Available online 5 June 2012AbstractPeak oxygen consumption (VO2) is one of the strongest predictors of survival in patients with chronic congestive heart failure (CHF), but it is
unavailable in most practices. Peak VO2 < 14 mL/kg/min identifies patients who might benefit from referral to a specialized CHF center.
Accordingly, the current study was undertaken to derive a prediction formula based on routine stress data obtained from patients referred for
cardiopulmonary exercise tolerance testing (CPETT). Subsequently, the prediction formula was validated in a separate cohort of similar patients
referred for CPETT at another institution. The derivation cohort consisted of 208 patients with a diagnosis of CHF with reduced systolic function
(left ventricular ejection fraction < 40%) who underwent elective CPETT. A multiple linear regression analysis was performed on available
treadmill testing variables. A simple prediction formula was derived: Predicted peak VO2 ¼ 16.7 e 1.3 (sex) e 3.8  (New York Heart
Association functional class) þ 0.04  (peak heart rate) þ 0.92  (estimated metabolic equivalents). The validation cohort consisted of 112
patients referred for CPETT at a different institution for the evaluation of advanced CHF. The predicted peak VO2 as obtained by the prediction
formula was compared to the actual peak VO2 using a Pearson coefficient of correlation. The predicted peak VO2 was well correlated with the
actual peak VO2 demonstrating a correlation coefficient of r ¼ 0.77 with a 95% confidence interval of (0.68e0.83). A simple prediction formula
using four variables that are routinely obtained in standard exercise treadmill testing can identify patients in whom formal CPETT is advisable
and facilitate early referral to specialized heart failure centers.
Copyright  2012, The Society of Chinese Scholars on Exercise Physiology and Fitness. Published by Elsevier (Singapore) Pte Ltd. This is an
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demonstrate whether exercise limitation is indeed cardiac in
etiology.1e3 It can be determined by analyzing the concen-
trations of O2 and CO2 in expired air during exercise with
rapidly responding gas analyzers capable of breath-by-breath
determination of O2 and CO2 concentrations.
4 CPETT is one
of the principal tests used to assess the risk/benefit ratio of
advanced therapies such as orthotopic heart transplantation
(OHT) or left ventricular assist device (LVAD) implantation in
patients with end-stage chronic congestive heart failurecise Physiology and Fitness. Published by Elsevier (Singapore) Pte Ltd. This is an open
/4.0/).
Table 1
Baseline clinical characteristics of study patients.
Characteristic Derivation cohort Validation cohort
Total patients (n) 208 112
Age (yr) 51  11 53  9
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year survival was 94%, whereas those patients with peak
VO2 < 14 mL/kg/min had a 1-year survival of 70%.
5 Patients
with peak VO2 < 12 mL/kg/min treated with b-adrenoceptor
blockers have a similar survival profile as patients not treated
and a peak VO2 < 14 mL/kg/min.
7 Despite the usefulness of
CPETT in the risk stratification of CHF, many tertiary centers
that treat patients with CHF do not have the capability of
performing CPETT. In contrast, standard exercise treadmill
testing (ETT) can be routinely carried out in most cardiology
practices.
Although there are multiple peak VO2 prediction formulas,
many of them are complicated or are derived from groups of
healthy volunteers. A large study that excluded patients with
severe CHF utilized several different formulas to predict peak
VO2, with the main variable being duration of exercise and
other variables being sex, weight, age and activity level.8
Other investigators have either derived or validated different
prediction formulas for peak VO2 obtained during CPETT.
Variables that have been commonly used in these formulas
include duration of exercise, workload (in metabolic equiva-
lents; METs), perceived workload (Borg scale), peak heart rate
(HR), sex, weight, age, activity level, height, and years of
exercise training.9e15 The Wasserman and Hansen formula,
which uses age, sex, mode of exercise, sedentary lifestyle,
height and weight to calculate a percent-predicted peak
VO2,16 has been well studied and shown to have prognostic
significance.17 However, many of these prediction formulas
require inputting several variables, thus, there may be a need
for a simpler formula that can easily be done during standard
ETT.
Accordingly, the present study was undertaken to identify
routine variables obtained during an electrocardiographic
exercise tolerance test that could reliably predict peak VO2. A
regression analysis was performed to create a best-fit, simple
formula that encompassed four variables: sex, peak HR, peak
workload (estimated METs) and New York Heart Association
(NYHA) functional class. Subsequently, this prediction
formula was validated by applying it to a separate cohort of
similar subjects referred for CPETT in the evaluation of
advanced CHF.Male sex (%) 74 77
LVEF (%) 23  7 23  6
ICM (%) 34 39
NIDCM (%) 66 61
NYHA functional class, %
I 0 12
II 33 45
III 67 55
Medications (%)
ACE inhibitors 85 78
ARBs 11 16
b-Blockers 69 92
Spironolactone 23 37
Digoxin 81 77
Diuretics 80 76
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker;
ICM ¼ ischemic cardiomyopathy; LVEF ¼ left ventricular ejection fraction;
NIDCM ¼ nonischemic cardiomyopathy; NYHA ¼ New York Heart
Association.Methods
This investigation was conducted in two parts. The deri-
vation cohort was studied at one CHF center and the validation
cohort was analyzed at a separate CHF center. Both parts of
the study were approved by their respective institutional
review boards.
Both cohorts were ambulatory patients with systolic CHF
[left ventricular ejection fraction (LVEF) < 40%], who were
physically capable of performing graded treadmill exercise for
a long enough duration to achieve a respiratory exchange ratio
(RER) > 1. The RER is the ratio of VCO2 to VO2 as measured
with the metabolic cart during the exercise protocol.
RER > 1.0 was taken as a surrogate for the patients havingexerted sufficient effort to stress their cardiovascular system
maximally beyond the anaerobic threshold. Many factors may
lead to a patient not obtaining an RER > 1.0, including
insufficient effort, claudication, musculoskeletal pain or
excessive dyspnea related to pulmonary disease. As a result of
this exclusion criterion, patients with significant gait impair-
ment or other mechanical disability were not enrolled. Addi-
tionally, patients were excluded if they had a left ventricular
assist device (LVAD), atrial fibrillation or resting dyspnea
(NYHA functional class IV).
The baseline clinical characteristics including background
medical therapy of both the derivation and validation cohorts
are shown in Table 1. In the derivation cohort, mean age was
51  11 years, mean LVEF was 23  7%, etiology of CHF
was ischemic heart disease in 34% of patients, 67% were
NYHA functional class III, and 74% were male. In the vali-
dation cohort, mean age was 53  9 years, mean LVEF was
23  6%, etiology of CHF was ischemic heart disease in 39%
of patients, 55% were NYHA functional class III, and 77%
were male.Derivation cohortBetween January 1, 2002 and June 30, 2003, 558 consec-
utive patients with a history of CHF were referred for initial
CPETT as a part of routine clinical testing or evaluation for
OHT. Patients who had undergone bicycle exercise ergometry
(n ¼ 49), with atrial fibrillation (n ¼ 38), with no information
on LVEF (n ¼ 60), with an unknown NYHA functional class
(n ¼ 47), had a LVAD (n ¼ 18), or failed to achieve an
RER > 1.0 (n ¼ 138) were excluded. Thus, 208 patients who
met the selection criteria for the derivation cohort were
analyzed.
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for CPETT were identified from January 1, 2008 until
December 30, 2010. Patients were included if they had been
referred for the test by a CHF specialist at that center and had
a LVEF < 40%. Patients were excluded if they were in atrial
fibrillation (n ¼ 15), could not achieve a RER > 1.0 (n ¼ 110),
had a LVAD (n ¼ 15), or if the information about their NYHA
functional class (n ¼ 17) or LVEF (n ¼ 4) was not docu-
mented in their medical records or if LVEF was  40%
(n ¼ 44). Thus, 112 patients who met the selection criteria for
the validation cohort were analyzed.CPETTPeak VO2 (mL/kg/min) was assessed during graded tread-
mill exercise. The work rate increased continuously in a step-
wise manner by augmenting the speed and grade of the
treadmill according to the Naughton protocol. Patients exer-
cised to a symptom-limited maximum. HR and electrocardi-
ography were recorded continuously during exercise and
blood pressure was measured at rest, and every 2 minutes
during exercise and during recovery. Expired gases were
collected throughout the protocol, and oxygen consumption
was calculated on a breath-by-breath basis (Sensormedics,
Yorba Linda, CA, USA). Peak VO2 was defined as the highest
value of oxygen uptake attained in the final 20 seconds of
exercise when RER was > 1.0.
At the second center where the validation cohort was
analyzed, the protocol for CPETT was similar, except the
metabolic cart was manufactured by Innovision (Innocor)
(Model # 500; Odense, Denmark) and the patients exercised
using a modified Naughton protocol. A similar RER > 1.0 was
taken as the cut-off for sufficient exercise during CPETT.Statistical analysisTable 2
Rest and exercise hemodynamics of study patients.
Derivation cohort Validation cohort
Peak VO2 (mL/kg/min) 17.5  6 16.0  5
Baseline HR (bpm) 75  13 71  11
Peak HR (bpm) 134  25 118  20
Baseline MAP (mmHg) 80  13 85  12
Peak MAP (mmHg) 91  14 91  16
HR ¼ heart rate; MAP ¼ mean arterial pressure; VO2 ¼ oxygen consumption.Multiple linear regression analysis was carried out to derive
the peak VO2 prediction formula using the data from the
derivation cohort. The analysis included 23 demographic and
clinical variables: age, sex, etiology of CHF, NYHA functional
class, medication use (b-adrenoceptor blocker, antiarrhythmic
therapy, digoxin, angiotensin converting enzyme inhibitor,
angiotensin receptor blocker, spironolactone, diuretic, and
statin), baseline mean arterial pressure (MAP), maximal MAP,
exercise time, RER, peak workload (estimated METs), base-
line HR, peak HR, peak HR change from baseline, HR at 1
minute post-exercise (HRR1) and HR at 2 minutes post-
exercise (HRR2). The backward selection technique was first
used to identify the variables significantly associated with
peak VO2 at the 5% level in the multiple linear regression. The
resulting model had an effect size (R2) of 0.85 and included
the variables of sex, NYHA functional class, peak workload
(estimated METs), peak HR, HRR1 and HRR2. As a result of
the high correlations among the HR variables, we decided to
include only peak HR, which gave the best prediction in theformula to achieve a more parsimonious model. The final
prediction formula was:
Predicted peak VO2 ¼ 16:7 e 1:3ðsexÞ e 3:8
 ðNYHA functional classÞ þ 0:04
 peak HR þ 0:92
 ðestimated METsÞ:
The correlation between peak VO2 and its prediction was
estimated by 0.90. Using this derived prediction formula, the
Pearson correlation coefficient was calculated between the
predicted peak VO2 and the actual peak VO2 in the validation
cohort. TJV was provided the variables to calculate the pre-
dicted peak VO2 and was blinded to the actual peak VO2. A
forward step-wise multiple regression model was used to
quantify predictors of peak VO2 using sex, peak HR, NYHA
functional class and peak workload (estimated METs) as
independent variables. These were chosen because they had
strong classifiers of having a low or high peak VO2. A p
value < 0.05 was considered statistically significant. All
analyses were conducted using SPSS 13.0 software.
Results
The rest and exercise hemodynamic data are summarized in
Table 2. In the derivation cohort, the mean peak VO2 was
17.5  6 mL/kg/min with 31% of the patients having a peak
VO2 < 14 mL/kg/min. The baseline HR was 75  13 bpm
with a peak HR of 134  25 bpm. The baseline MAP was
80  13 mmHg and the peak MAP was 91  14 mmHg. In the
validation cohort, the mean peak VO2 was 16.0  5 mL/kg/
min with 32% of the patients having a peak VO2 < 14 mL/kg/
min. The baseline HR was 71  11 bpm, peak HR was
118  20 bpm, baseline MAP was 85  12 mmHg and peak
MAP was 91  16 mmHg.
Using the simple formula to predict the peak VO2 obtained
by patients in the validation cohort, there was a moderate and
statistically significant correlation coefficient of 0.77
( p < 0.0001) with a 95% confidence interval of (0.68e0.83)
(Fig. 1).
Using a forward step-wise regression model to predict peak
VO2, peak HR explained the greatest percentage of variance in
peak VO2 (31%), followed by NYHA functional class (30%),
peak estimated METs (14%) and sex (5%) ( p < 0.001 for
model, Table 3). The multiple R from the regression equation
was 0.89 and R2 was 0.80.
Fig. 1. Scatter plot with best-fit trend line. R ¼ 0.77 (confidence interval 0.68e0.83; p < 0.0001).
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A prediction formula for peak VO2 was created based on
208 patients with CHF referred for CPETT and subsequently
validated in 112 patients with similar baseline clinical char-
acteristics. The variables of peak HR, estimated METs, NYHA
functional class and sex were highly significant in predicting
peak VO2. If this formula can be validated in prospective
studies, then centers that do not have a metabolic cart and
trained personnel required to perform CPETT would have an
additional tool for the selection of patients that would benefit
from early referral to centers for formal CPETT and OHT or
LVAD evaluation.
Separately, the factors in this proposed formula for pre-
dicting peak VO2 have been shown to correlate with the actual
peak VO2. In an analysis of 1750 patients in the HF-ACTION
database, NYHA functional class II corresponded to a peak
VO2 of 16.1  4.6 mL/kg/min versus 13.0  4.2 mL/kg/min in
patients that were NYHA functional class III.17 Maximal HR
achieved is preserved in patients with a healthy response to
exercise, and has been shown to correlate with peak VO2.18 In
CHF, it has been shown that 30e50% of patients cannot ach-
ieve 80% of their maximal predicted HR, and are thus chro-
notropically incompetent. In one analysis of 278 patients
undergoing CPETT, chronotropic incompetence correlated
with a decreased peak VO2 (average 15.4 mL/kg/min) andTable 3
Correlation matrix between clinical, demographic and exercise variables.
Variable R R2 Added variance
explained (%)
p value
Sex 0.22 0.05 5 0.002
Peak HR 0.60 0.36 31 < 0.001
NYHA functional class 0.81 0.66 30 < 0.001
Peak estimated METs 0.89 0.80 14 < 0.001
HR ¼ heart rate; METs ¼ metabolic equivalents; NYHA ¼ New York Heart
Association.mean decreased peak HR (114 bpm) as compared to CHF
patients devoid of chronotropic incompetence, who had a mean
peak VO2 of 19.9 mL/kg/min and mean peak HR of 152 bpm.
19
Male patients are associated with a consistently higher peak
VO2 (about 1.6 mL/kg/min) than female patients, regardless of
NYHA functional class.20,21 Finally, decreased workload has
also been shown to be prognostic of 1-year mortality and
correlates with peak VO2 in patients with CHF.
9,22
Although blinded to the actual variables, our study was
mainly limited by the fact that the validation cohort was
analyzed retrospectively. The exercise protocol in the deriva-
tion cohort was a Naughton protocol, whereas in the validation
cohort, it was a modified Naughton protocol. This is unlikely
to have affected the results of the correlation found with the
prediction formula because both groups exercised to
a symptom-limited maximum. Additionally, it has been shown
that the peak VO2 obtained during CPETT is similar between
different exercise protocols.23 Another limitation of this
prediction formula is that it is unlikely to predict accurately
peak VO2 in patients without CHF or patients with symp-
tomatic CHF and preserved systolic function. The latter group
of patients has an equivalent mortality to CHF patients with
reduced systolic function.24
A theoretical limitation of this formula is the potential that
the relationship between peak VO2 and the exercise treadmill
variables used is not linear. In the original prediction formulas
derived by Bruce et al,9 there are different formulas for
treadmill performance (submaximal or maximal effort),
sedentary lifestyle and cardiac status, with the result being
a nonlinear model using multiple formulas It is possible that
the correlation of this formula in the present study was
preserved because patients were excluded if they did not
achieve an anaerobic threshold or RER > 1.0. The only way to
test whether this simple prediction formula can predict peak
VO2 in patients with a submaximal CPETT is to test it
prospectively in all patients, regardless of RER obtained,
which may be difficult because there are many non-
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exercise on a treadmill protocol.
Taken together, these four variables that are easily obtain-
able during a routine stress test in a practitioner’s office could
potentially allow the estimation of a patient’s peak VO2, and
signal the need for referral for further evaluation at a center
with advanced CHF capabilities. This simple formula for
predicting peak VO2 cannot replace a CPETT, but if further
validated in prospective studies, could offer another tool for
the general cardiologist in the management of patients with
CHF. Additionally, if this prediction formula is again validated
on a larger scale, it could potentially be incorporated into risk
stratification models like the Heart Failure Survival Score,
further enhancing its prognostic potential.
In conclusion, the current study proposes a formula for
predicting peak VO2 based on variables that are easily ob-
tained from routine ETT. If validated by prospective studies, it
offers an additional, low-cost tool for the risk-stratification and
management of patients with CHF.References
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